Cogent Biosciences
COGT
149 hedge funds and large institutions have $1.02B invested in Cogent Biosciences in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 22 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
39% more capital invested
Capital invested by funds: $734M → $1.02B (+$289M)
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
21.84% more ownership
Funds ownership: 105.14% → 126.98% (+22%)
13% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 48
2% more funds holding
Funds holding: 146 → 149 (+3)
12% less call options, than puts
Call options by funds: $1.68M | Put options by funds: $1.91M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.8M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$27.5M |
| 3 |
CC
Commodore Capital
New York
|
+$25.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.1M |
| 5 |
DM
Deerfield Management
New York
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$28.7M |
| 2 |
Janus Henderson Group
London,
|
-$15.8M |
| 3 |
Millennium Management
New York
|
-$8.53M |
| 4 |
Morgan Stanley
New York
|
-$6.59M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.94M |
COGT Hedge Fund Activity: Q2 2024 in Review
149 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2024, worth a combined $1.02B — up 39% from $734M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new COGT positions and 22 closed out — a net gain of 6 holders — while 54 added to existing stakes and 48 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $28.8M. The largest seller was State Street, cutting an estimated $28.7M.
- 149 institutional investors held Cogent Biosciences (COGT) as of Q2 2024, up from 146 in Q1 2024.
- Funds reported $1.02B of Cogent Biosciences stock for Q2 2024, up 39% quarter-over-quarter.
- 28 funds opened new Cogent Biosciences positions in Q2 2024 and 22 closed out, a net change of +6 holders.
- The largest Cogent Biosciences buyer in Q2 2024 was Point72 Asset Management, an estimated $28.8M added.
- The largest Cogent Biosciences seller in Q2 2024 was State Street, an estimated $28.7M sold.
Based on aggregated 13F filings for Q2 2024.